Safety and Preliminary Efficacy Assessment of AZD7789 in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Trial Identifier: D9571C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT05216835
Start Date: March 2022
Primary Completion Date: February 2026
Study Completion Date: October 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, Ontario Toronto, Ontario, CA, M5G 1X6
CA, QC Montreal, QC, CA, H3T 1E2
CN Beijing, CN, 100036
CN Zhengzhou, CN, 450008
DE Köln, DE, 50924
DK København Ø, DK, 2100
DK Odense, DK, 5000
ES Barcelona, ES, 8035
ES Valencia, ES, 46010
FR LILLE CEDEX, FR, 59037
FR Paris, FR, 75010
FR Villejuif, FR, 94805
GB Manchester, GB, M20 4BX
GB Oxford, GB, 0X3 7LJ
IT Bologna, IT, 40138
IT Milan, IT, 20141
IT Napoli, IT, 80131
US, CA Duarte, CA, US, 91010
US, FL Miami, FL, US, 33136
US, MA Boston, MA, US, 02215
US, MN Rochester, MN, US, 55905
US, NY New York, NY, US, 10065
US, TX Houston, TX, US, 77030